Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
[widgetkit id="1" name="CC Event Nav"]
Treatment with a Novel HDAC6 Inhibitor plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Read More
Sustained Overall Survival in Patients with Smoldering Myeloma Receiving Lenalidomide-Based Therapy
Read More
Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages
Read More
Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance: Data from the Connect MM Disease Registry
Read More
Ixazomib, Pomalidomide, and Dexamethasone Triplet Therapy in Patients with Double/Triple Refractory Myeloma
Read More
Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen
Read More
PREAMBLE: Real-World Efficacy Analyses in Multiple Myeloma Patients with One Line of Prior Therapy
Read More
Retreatment with Daratumumab and Pomalidomide Among Refractory Patients with Multiple Myeloma
Read More
Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Read More
A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse
Read More
15
16
17
18
19
20
21
Page 18 of 25
Results 171 - 180 of 242